Trending stocks today
Intellia Therapeutics (NTLA-Q)
NASDAQ:NTLA
9.14
0.08
(0.87%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 2 opinions in the last 12 months.
Intellia Therapeutics (NTLA) operates in the high-risk but high-reward biotech sector, leveraging CRISPR technology to combat autoimmune and rare diseases. With total cash and short-term investments amounting to $912.2 million, of which $226.7 million is in cash and equivalents, they are well-funded for ongoing research and development. However, analysts express caution as the company is expected to face significant unprofitability in the near future, even with projected revenue growth of 40% this year before plateauing in 2025. Insider ownership is relatively low at 9.39%, and the firm's growth largely hinges on the successful market introduction of its product NTLA-2001. Despite these risks, there is optimism reflected in the positive recommendations from analysts, with a consensus buy rating and a projected target price of $69.96.
Biotech is an exciting area to be looking at. It is higher growth but higher risk - along with higher reward. Biotech has under-performed for the past two years. Intellia has used crisper technology to target mutated genes dealing with autoimmune and rare diseases - and try to cure them. They are at third stage trials this year. It has $2 billion cash which is good for two years of R&D. Management is good. Buy 25 Hold 6 Sell 0
(Analysts’ price target is $69.96)- «
- ‹
- 1
- ›
- »
Intellia Therapeutics(NTLA-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Intellia Therapeutics(NTLA-Q) Frequently Asked Questions
What is Intellia Therapeutics stock symbol?
Intellia Therapeutics is a American stock, trading under the symbol NTLA-Q on the NASDAQ (NTLA). It is usually referred to as NASDAQ:NTLA or NTLA-Q
Is Intellia Therapeutics a buy or a sell?
In the last year, 1 stock analyst published opinions about NTLA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Intellia Therapeutics.
Is Intellia Therapeutics a good investment or a top pick?
Intellia Therapeutics was recommended as a Top Pick by on . Read the latest stock experts ratings for Intellia Therapeutics.
Why is Intellia Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Intellia Therapeutics worth watching?
1 stock analyst on Stockchase covered Intellia Therapeutics In the last year. It is a trending stock that is worth watching.
What is Intellia Therapeutics stock price?
On 2025-03-14, Intellia Therapeutics (NTLA-Q) stock closed at a price of $9.14.
NTLA has $912.2M in total cash and short term investments. Cash and equivalents is $226.7M while $685.5M is in short term investments. Insider ownership is 9.39%. NTLA is expected to be highly unprofitable over the next three years, but revenue is expected grow at 40% this year, then flat in 2025. We think it is a very speculative play and it is also highly unprofitable and burning through cash at a high rate. Share price appreciation will be reliant on bringing NTLA-2001 to market.
Unlock Premium - Try 5i Free